Chronic Plaque Psoriasis

References

• Naldi L. Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy 2004; 3: 121–8.
   Google Scholar
• Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985; 13: 450–6.
   PubMed Web of Science ®Google Scholar
• Giardina E, Sinibaldi C, Novelli G. The psoriasis genetics as a model of complex disease. Curr Drug Targets Inflamm Allergy 2004; 3: 129–36.
   PubMedGoogle Scholar
• Ozawa M, Aiba S. Immunopathogenesis of psoriasis. Curr Drug Targets Inflamm Allergy 2004; 3: 137–44.
   PubMedGoogle Scholar
• Asadullah K, Volk HD, Sterry W. Novel immunotherapies for psoriasis. Trends Immunol 2002; 23: 47–53.
   PubMed Web of Science ®Google Scholar
• Abel EA, DiCicco LM, Orenberg EK, Fraki JE, Farber EM. Drugs in exacerbation of psoriasis. J Am Acad Dermatol 1986; 15(5 pt 1): 1007–22.
   Google Scholar
• Picardi A, Abeni D. Stressful life events and skin diseases: disentangling evidence from myth. Psychother Psychosom 2001; 70: 118–36.
   PubMed Web of Science ®Google Scholar
• Namazi MR. Paradoxical exacerbation of psoriasis in AIDS: proposed explanations including the potential roles of substance P and gram-negative bacteria. Autoimmunity 2004; 37: 67–71.
   PubMed Web of Science ®Google Scholar
• Yosipovitch G, Goon A, Wee J, Chan YH, Goh CL. The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. Br J Dermatol 2000; 143: 969–73.
   PubMed Web of Science ®Google Scholar
• Tham SN, Lim JJ, Tay SH, Chiew YF, Chua TN, Tan E, et al. Clinical observations on nail changes in psoriasis. Ann Acad Med Singapore 1988; 17: 482–5.
   PubMedGoogle Scholar
• Biondi Oriente C, Scarpa R, Pucino A, Oriente P. Psoriasis and psoriatic arthritis. Dermatological and rheumatological co-operative clinical report. Acta Derm Venereol Suppl (Stockh) 1989; 146: 69–71.
   PubMedGoogle Scholar
• Scarpa R, Oriente P, Pucino A, Torella M, Vignone L, Riccio A, et al. Psoriatic arthritis in psoriatic patients. Br J Rheumatol 1984; 23: 246–50.
   PubMedGoogle Scholar
• Russo PA, Ilchef R, Cooper AJ. Psychiatric morbidity in psoriasis: a review. Australas J Dermatol 2004; 45: 155–61.
   PubMedGoogle Scholar
• Margolis D, Bilker W, Hennessy S, Vittorio C, Santanna J, Strom BL. The risk of malignancy associated with psoriasis. Arch Dermatol 2001; 137: 778–83.
   PubMed Web of Science ®Google Scholar
• Al-Suwaidan SN, Feldman SR. Clearance is not a realistic expectation of psoriasis treatment. J Am Acad Dermatol 2000; 42(5 pt 1): 796–802.
   Google Scholar
• Naldi L, Rzany B. Chronic plaque psoriasis. Clin Evid 2004; (11): 2140–67.
   Google Scholar
• Mason J, Mason AR, Cork MJ. Topical preparations for the treatment of psoriasis: a systematic review. Br J Dermatol 2002; 146: 351–64.
   PubMed Web of Science ®Google Scholar
• Ashcroft DM, Po AL, Williams HC, Griffiths CE. Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. BMJ 2000; 320: 963–7.
   PubMed Web of Science ®Google Scholar
• Weinstein GD, Koo JY, Krueger GG, Lebwohl MG, Lowe NJ, Menter MA, et al. Tazarotene cream in the treatment of psoriasis: two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol 2003; 48: 760–7.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Ast E, Callen JP, Cullen SI, Hong SR, Kulp-Shorten CL, et al. Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis. J Am Acad Dermatol 1998; 38(5 pt 1): 705–11.
   Google Scholar
• Lebwohl MG, Breneman DL, Goffe BS, Grossman JR, Ling MR, Milbauer J, et al. Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. J Am Acad Dermatol 1998; 39(4 pt 1): 590–6.
   Google Scholar
• Bruner CR, Feldman SR, Ventrapragada M, Fleischer ABJr. A systematic review of adverse effects associated with topical treatments for psoriasis. Dermatol Online J 2003; 9: 2.
   PubMedGoogle Scholar
• Zonneveld IM, Rubins A, Jablonska S, Dobozy A, Ruzicka T, Kind P, et al. Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study [published correction appears in Arch Dermatol 1998; 134: 1386]. Arch Dermatol 1998; 134: 1101–2.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Freeman AK, Chapman MS, Feldman SR, Hartle JE, Henning A. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol 2004; 51: 723–30.
   PubMed Web of Science ®Google Scholar
• Gribetz C, Ling M, Lebwohl M, Pariser D, Draelos Z, Gottlieb AB, et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol 2004; 51: 731–8.
   PubMed Web of Science ®Google Scholar
• Wooltorton E. Eczema drugs tacrolimus (Protopic) and pimecrolimus (Elidel): cancer concerns. CMAJ 2005; 172: 1179–80.
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Clark CM, Chalmers RJ, Li Wan Po A, Williams HC. A systematic review of treatments for severe psoriasis. Health Technol Assess 2000; 4: 1–125.
   PubMedGoogle Scholar
• Katz HI, Prawer SE, Medansky RS, Krueger GG, Mooney JJ, Jones ML, et al. Intermittent corticosteroid maintenance treatment of psoriasis: a doubleblind multicenter trial of augmented betamethasone dipropionate ointment in a pulse dose treatment regimen. Dermatologica 1991; 183: 269–74.
   PubMedGoogle Scholar
• Douglas WS, Poulin Y, Decroix J, Ortonne JP, Mrowietz U, Gulliver W, et al. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol 2002; 82: 131–5.
   PubMed Web of Science ®Google Scholar
• Papp KA, Guenther L, Boyden B, Larsen FG, Harvima RJ, Guilhou JJ, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol 2003; 48: 48–54.
   PubMed Web of Science ®Google Scholar
• Krueger GG. Current concepts and review of alefacept in the treatment of psoriasis. Dermatol Clin 2004; 22: 407–26.
   Google Scholar
• Leonardi CL. Current concepts and review of efalizumab in the treatment of psoriasis. Dermatol Clin 2004; 22: 427–35.
   PubMed Web of Science ®Google Scholar
• Yamauchi PS, Gindi V, Lowe NJ. The treatment of psoriasis and psoriatic arthritis with etanercept: practical considerations on monotherapy, combination therapy, and safety. Dermatol Clin 2004; 22: 449–59.
   PubMed Web of Science ®Google Scholar
• Winterfield L, Menter A. Psoriasis and its treatment with infliximab-mediated tumor necrosis factor alpha blockade. Dermatol Clin 2004; 22: 437–47.
   PubMed Web of Science ®Google Scholar
• Snellman E. Psoriasis. In: EBM guidelines. Evidence-based medicine (CDROM). Helinski, Finland: Duodecim Medical Publications Ltd., 2004. Accessed online December 19, 2005, at: http://www.guideline.gov/summary/summary.aspx?ss=15&doc_id=8260.
   Google Scholar